ArticleCardiovascular psychiatry and neurology2010
Mood disorders are glial disorders: evidence from in vivo studies.
Article in Cardiovascular psychiatry and neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review.Molecular psychiatry · 2020Pooled it
- Trial
- Single-cell multiomics analysis reveals cell/tissue-specific associations in bipolar disorder.Translational psychiatry · 2024Article
- How S100B crosses brain barriers and why it is considered a peripheral marker of brain injury.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder.Advances in experimental medicine and biology · 2023Review
- Ketogenic Diet and Inflammation: Implications for Mood and Anxiety Disorders.Advances in experimental medicine and biology · 2023Review
- Binding and Functional Folding (BFF): A Physiological Framework for Studying Biomolecular Interactions and Allostery.Journal of molecular biology · 2022Review
- Increased Serum NSE and S100B Indicate Neuronal and Glial Alterations in Subjects Under 71 Years With Mild Neurocognitive Disorder/Mild Cognitive Impairment.Frontiers in cellular neuroscience · 2022Article
- Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.Translational psychiatry · 2021Article
- Article
- The Ketamine Antidepressant Story: New Insights.Molecules (Basel, Switzerland) · 2020Review
- Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study.Purinergic signalling · 2019Article
- Structural Basis for S100B Interaction with its Target Proteins.Journal of molecular and genetic medicine : an international journal of biomedical research · 2018Article
- Scolopendra Pharmacopuncture Ameliorates Behavioral Despair in Mice Stressed by Chronic Restraint.Journal of pharmacopuncture · 2017Article
- Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case-control study.Bioscience reports · 2017Article
- Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model.Behavioral and brain functions : BBF · 2016Article
- Low-Dimensional Models of "Neuro-Glio-Vascular Unit" for Describing Neural Dynamics under Normal and Energy-Starved Conditions.Frontiers in neurology · 2016Article
- Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers.Psychiatry investigation · 2016Review
- Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia-A Meta-Regression Analysis.Frontiers in cellular neuroscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has recently been suggested that mood disorders can be characterized by glial pathology as indicated by histopathological postmortem findings. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. This protein might act as a growth and differentiation factor. It is located in, and may actively be released by, astro- and oligodendrocytes. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Successful antidepressive treatment reduces S100B in major depression whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered. By indicating glial alterations without neuronal changes, serum S100B studies confirm specific glial pathology in mood disorders in vivo. S100B can be regarded as a potential diagnostic biomarker for mood disorders and as a biomarker for successful antidepressive treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.